ROCO
6617
Market cap451mUSD
Oct 08, Last price
119.00TWD
1D
-2.06%
1Q
8.18%
IPO
36.99%
Name
Gongwin Biopharm Holdings Co Ltd
Chart & performance
P/E
—
P/S
395.76
EPS
—
Div yield, %
—
Shrs. gr., 5y
3.15%
Rev. gr., 5y
112.91%
Revenues
36m
+13.75%
Net income
-114m
L+38.25%
CFO
-136m
L+55.31%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Gongwin Biopharm Holdings Co., Ltd. is a clinical-stage biopharmaceutical company specializing in the development of oncology therapeutics. The company's robust pipeline features several drug candidates, including PTS302, which has successfully concluded Phase III clinical trials for lung cancer. Additionally, PTS100 is currently progressing through Phase II clinical trials for liver cancer, while PTS-02 is being developed to address adenoid cystic carcinoma, and PTS500 targets malignant pleural effusion. Established in 2014, Gongwin Biopharm is headquartered in Taipei, Taiwan.
Key people
Lester Wu
Chairman of the Board · since 2016
Wei Nan Hu
Chief Financial Officer, Corporate Governance Officer · since 2023
Si Liu
General Manager-Tianjin · since 2022
Li Tian
Deputy General Manager-Tianjin · since 2015
Charles Yang
Deputy General Manager · since 2016
Shaowen Guo
Director · since 2016
Mao Yuan Lin
General Manager, Director · since 2016
Jixiu Liu
Director · since 2018
Youhua Yang
Director · since 2023
Lielin Zhan
Director · since 2018
Independent Director · since 2020
Zhidong Yang
Independent Director · since 2016
Weida Zheng
Independent Director · since 2016
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||